Invesco
CMPX icon

Invesco’s Compass Therapeutics CMPX Stock Holding History

Invesco’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$535K Buy
101,207
+37,306
+58% +$215K ﹤0.01% 3138
2025
Q4 		$343K Buy
63,901
+3,245
+5% +$15K ﹤0.01% 3334
2025
Q3 		$212K Buy
60,656
+1,921
+3% +$6.07K ﹤0.01% 3548
2025
Q2 		$153K Buy
58,735
+21,578
+58% +$44.5K ﹤0.01% 3579
2025
Q1 		$70.6K Sell
37,157
-2,326
-6% -$6.18K ﹤0.01% 3672
2024
Q4 		$57.3K Buy
39,483
+4,018
+11% +$6.67K ﹤0.01% 3679
2024
Q3 		$65.3K Sell
35,465
-1,937
-5% -$2.41K ﹤0.01% 3659
2024
Q2 		$37.4K Sell
37,402
-4,361
-10% -$6.37K ﹤0.01% 3845
2024
Q1 		$82.7K Sell
41,763
-1,427
-3% -$2.47K ﹤0.01% 3762
2023
Q4 		$67.4K Sell
43,190
-22,906
-35% -$39.6K ﹤0.01% 3730
2023
Q3 		$130K Buy
66,096
+27,452
+71% +$67.9K ﹤0.01% 3685
2023
Q2 		$123K Buy
+38,644
New +$121K ﹤0.01% 3691

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco's CMPX Position: Q1 2026 in Review

Invesco increased its Compass Therapeutics (CMPX) stake by 58% in Q1 2026, buying an estimated $215K and bringing the position to 101,207 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

Invesco first reported a position in CMPX in Q2 2023 and has held it in 12 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Invesco held 101,207 shares of Compass Therapeutics worth $535K as of Q1 2026.
  • Invesco bought 37,306 Compass Therapeutics shares in Q1 2026, an estimated $215K.
  • Compass Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3138 holding.
  • Invesco first reported a position in Compass Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.